A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics

Endogenous microRNAs (miRNA) in tumors are currently under exhaustive investigation as potential therapeutic agents for and untargeted delivery, limited biological effect, and currently unclear side effects remain unsettled issues that frustrate clinical application. To address this, a versatile targeted delivery system for multiple therapeutic and diagnostic agents should be adapted for miRNA. In this study, we developed membrane-coated sulating doxorubicin (Dox) and miRNA-190-Cy7. Such a system showed low biotoxicity, high loading efficiency, and superior targeting ability. Systematic delivery of m-PPDCNPs in mouse models showed exceptionally specific tumor accumulation. Sustained release of miR-190 inhibited tumor angiogenesis, tumor growth, and migration by regulating a large group of angiogenic effectors. Moreover, m-PPDCNPs also enhanced the sensitivity lines and mouse models. Together, our results demonstrate a stimulating and promising m-PPDCNPs nanoplatform for colorectal cancer theranostics.

Automated summary

In this study, a membrane-coated delivery system was developed for the therapeutic and diagnostic use of miRNA in tumors. The system showed low toxicity, high loading efficiency, and superior targeting ability. It inhibited tumor angiogenesis, growth, and migration, making it a promising nanoplatform for colorectal cancer theranostics.